Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: You gotta ask yourself

"Based on the current status where TPL gets 95% of the revenue from a $7M licensing quarter, what is their incentive to bring a speedy conclusion to the T3 situation?! "

You don't think this statement is at all misleading? I would think it is relevant to point out the fact that of that "95% of the revenue" TPL got, more than half of it was a reimbursed expense - TPL had already shelled out $4.85 million of their own money and we were paying them back. Since PTSC is also a litigant in the T3 case are you implying that our lawyers would be handling the case so as to damage PTSC while at the same time enabling TPL? Do you think PTSC has no input with the lawyers handling the T3 case? If so, please cite some reference that would indicate this.

Share
New Message
Please login to post a reply